Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009

Journal of Korean Medical Science

Volumn 25, Issue 2, 2010, Pages 251-256

  Chang, Seung Gu ^a   Park, Moon Sung ^a   Yu, Jae Eun ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chronic lung disease; Hospitalization; Palivizumab prophylaxis; Preterm children; Respiratory syncytial viruses

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; PALIVIZUMAB;

ARTICLE; DEMOGRAPHY; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; NEWBORN; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHOPULMONARY DYSPLASIA; DEMOGRAPHY; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; PREMATURE BIRTH; REPUBLIC OF KOREA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77951634917     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.2.251     Document Type: Article

References (25)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl Med 2001; 344: 1917-28.
2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-70.
3. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003; 22: 483-90.
4. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118: 1774-93.
5. Loughlin GM, Moscona A. The cell biology of acute childhood respiratory disease: therapeutic implications. Pediatr Clin North Am 2006; 53: 929-59.
6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86.
7. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94: 99-103.
8. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143 (5 Suppl): S150-6.
9. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-9.
11. Denny FW, Clyde WA Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 1986; 108: 635-46.
12. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354: 847-52.
13. Kim YK, Nyambat B, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis 2008; 40: 946-53.
14. Ahn KM, Chung SH, Chung EH, Koh YJ, Nam SY, Kim JH, Son JA, Park JY, Lee NY, Lee SI. Clinical characteristics of acute viral lower respiratory tract infections in hospitalized children in Seoul, 1996-1998. J Korean Med Sci 1999; 14: 405-11.
15. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect 2000; 41: 152-8.
16. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, Lee JH, Song EK, Kim SH, Park JY, Sung JY. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin Infect Dis 2006; 43: 585-92.
17. Lee EA, Jeong JH, Yu ST, Lee CW, Yoon HS, Park DS, Oh YK. Incidence and risk factors of rehospitalization with respiratory syncytial virus infection in premature infants. Korean J Pediatr 2004; 47: 510-4.
18. Centers for Disease Control and Prevention (CDC). Brief report: respiratory syncytial virus activity-United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2006; 55: 1277-9.
19. Oh PI, Lanctĵt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002; 21: 512-8.
20. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000; 19: 1068-71.
21. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28: 511-7.
22. Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35: 484-9.
23. Saji BT. Indications, efficacy and Safety of Anti-RS Virus Monoclonal Antibody Palivizumab (Synagis) for Pediatric Patients With Congenital Heart Diseases. J Korean Pediatr Cardiol Soc 2007; 11: 149-50.
24. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442-6.
25. th ed. Elk Grove, IL: American Academy of Pediatrics; 2006.